Cognios Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-7,096
Closed -$530K 95
2020
Q1
$530K Hold
7,096
0.26% 117
2019
Q4
$461K Hold
7,096
0.16% 121
2019
Q3
$449K Sell
7,096
-630
-8% -$41.2K 0.17% 122
2019
Q2
$521K Sell
7,726
-9,353
-55% -$615K 0.2% 116
2019
Q1
$1.11M Sell
17,079
-1,857
-10% -$123K 0.39% 112
2018
Q4
$1.18M Sell
18,936
-859
-4% -$60K 0.48% 101
2018
Q3
$1.53M Sell
19,795
-3,045
-13% -$230K 0.63% 100
2018
Q2
$1.62M Sell
22,840
-1,576
-6% -$111K 0.57% 99
2018
Q1
$1.84M Sell
24,416
-1,779
-7% -$141K 0.67% 92
2017
Q4
$1.88M Sell
26,195
-15,465
-37% -$1.17M 0.71% 91
2017
Q3
$3.38M Sell
41,660
-6,550
-14% -$501K 1.37% 10
2017
Q2
$3.41M Sell
48,210
-137,896
-74% -$9.18M 1.19% 15
2017
Q1
$12.6M Buy
186,106
+81,219
+77% +$5.71M 4.19% 2
2016
Q4
$7.51M Sell
104,887
-985
-0.9% -$73.2K 2.29% 18
2016
Q3
$8.38M Sell
105,872
-48,456
-31% -$3.94M 2.39% 16
2016
Q2
$12.9M Buy
154,328
+36,212
+31% +$3.21M 4.09% 2
2016
Q1
$10.8M Buy
118,116
+69,019
+141% +$6.22M 4.05% 2
2015
Q4
$4.97M Buy
49,097
+11,116
+29% +$1.16M 2.53% 12
2015
Q3
$3.73M Buy
+37,981
New +$4.22M 2.16% 19

Other funds holding GILD

Cognios Capital's GILD Position: Q2 2020 in Review

Cognios Capital sold out of Gilead Sciences (GILD) in Q2 2020, closing a stake of 7,096 shares — an estimated $530K sold.

Cognios Capital first reported a position in GILD in Q3 2015 and held it in 19 quarters. The position peaked at $12.9M in Q2 2016. 1,626 funds tracked by Wall St. Rank hold GILD as of Q2 2020.

  • Cognios Capital reported no remaining Gilead Sciences position as of Q2 2020 after selling out during the quarter.
  • Cognios Capital sold 7,096 Gilead Sciences shares in Q2 2020, an estimated $530K.
  • Cognios Capital first reported a position in Gilead Sciences in Q3 2015 and held it in 19 quarters.
  • Cognios Capital's Gilead Sciences position peaked at $12.9M in Q2 2016.
  • 1,626 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2020.

Based on Cognios Capital's 13F filing for Q2 2020.